---
schema_version: "secwatch.filing_event.v1"
accession: "0000059478-24-000185"
form_type: "8-K"
ticker: "LLY"
cik: "0000059478"
company_name: "ELI LILLY & Co"
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:24:14.841459+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Lilly Q2 revenue up 36% to $11.3B, raises FY revenue guidance by $3B

## Summary
- Q2 revenue $11.30B (+36% YoY); reported EPS $3.28 (+68%), non-GAAP EPS $3.92 (+86%).
- FY revenue guidance raised $3B; reported EPS raised $2.05 to $15.10-15.60; non-GAAP EPS raised $2.60 to $16.10-16.60.
- Growth driven by Mounjaro, Zepbound, and Verzenio; non-incretin revenue up 17% ex-Baqsimi rights sale.
- Pipeline: FDA approval of Kisunla for Alzheimer's; tirzepatide submissions for sleep apnea; positive SUMMIT and QWINT trials.
- Announced agreement to acquire Morphic Holding for oral integrin therapies; $5.3B manufacturing investment in Indiana.

## SEC filing metadata
- accession: 0000059478-24-000185
- form_type: 8-K
- ticker: LLY
- cik: 0000059478
- company_name: ELI LILLY & Co
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/59478/000005947824000185/0000059478-24-000185-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/59478/000005947824000185/lly-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000059478-24-000185
- JSON: https://secwatch.observer/filing/0000059478-24-000185.json
- Plain text: https://secwatch.observer/filing/0000059478-24-000185.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.